Role of p53-mediated unconventional functions in tumor suppression
Role of p53-mediated unconventional functions in tumor suppression
批准号:
8551651
负责人:
Wei Gu
金额:
$31.0万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-26 至 2017-08-31
关键词:
8-hydroxy-2&apos-deoxyguanosineAcetylationAnimalsAntioxidantsApoptosisApoptoticArginineCell AgingCell Cycle ArrestCell DeathCellsCellular StressDNADNA BindingDNA DamageDataDeoxyguanosineEventGLS2 geneGene TargetingGenerationsGenesGenetic TranscriptionGlycolysisHumanHypoxiaKnockout MiceLinkLysineMalignant NeoplasmsMediatingMetabolicMicroarray AnalysisMitochondriaModificationMolecularMolecular ProfilingMonitorMusMutant Strains MiceMutationNucleotidesOncogene ActivationOncogenesOncogenicOxidative PhosphorylationOxidative StressPathway interactionsPatientsPhysiologicalPlayProcessProductionProtein p53Reactive Oxygen SpeciesRegulationRespirationRoleSignal PathwaySiteSomatic MutationStressTP53 geneTestingThymic LymphomaTumor SuppressionTumor Suppressor ProteinsWarburg Effectbasebiological adaptation to stresscancer cellcancer riskcell growthearly onsetin vivoneoplastic celloxidationpromoterpublic health relevancesenescencesensortranscription factortumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): There is accumulating evidence indicating that p53 is critical in regulation of glycolysis, reactive oxygen species (ROS) production and oxidative stress responses under normal physiological conditions. A number of studies showed that loss of p53 results in decreased mitochondrial respiration and enhanced glycolysis, leading to the Warburg effect. p53 also induces several antioxidant genes, including TIGAR and GLS2, to reduce the levels of reactive oxygen species (ROS). Notably, ROS production causes DNA damage through oxidation of nucleotide bases by increasing 8-hydroxy-22-deoxyguanosine (8-OH-dG) levels. Thus, antioxidant activities of p53 are involved in limiting DNA damage through reducing ROS levels. Nevertheless, it remains unclear whether this part of p53 functions directly contributes to the role of p53 as a tumor suppressor. We have recently demonstrated that acetylation of p53 is required for its activation of cell cycle arrest and apoptosis. In our preliminary studies, we have generated mice bearing lysine to arginine mutations at one (p53K117R) or three (p533KR; K117R+K161R+K162R) of the critical p53 acetylation sites. While p53K117R/K117R cells are competent for p53-mediated cell-cycle arrest and senescence, but not apoptosis, all three of these processes are ablated in p533KR/3KR cells. Surprisingly, unlike p53-null mice, which rapidly succumb to spontaneous thymic lymphomas, early-onset tumor formation does not occur in either p53K117R/K117R or p533KR/3KR animals. Since p533KR/3KR mice lack
p53-mediated cell cycle arrest, apoptosis, and senescence, this observation suggests that other aspects of p53 function are sufficient for suppression of early-onset tumorigenesis. Notably, p533KR retains the ability to transactivate metabolic target genes, such as TIGAR and GLS2, and subsequently suppresses glycolysis and reactive oxygen species (ROS) production. The central hypothesis to be tested here is whether p53-mediated effects in glycolysis, ROS production and oxidative stress responses act as an independent mechanism in tumor suppression in the absence of cell-cycle arrest, apoptosis and senescence. The proposed studies include the following two specific aims. In Aim 1, we will dissect the role of p53 in regulating reactive oxyge species (ROS) production, oxidative stress responses and glycolysis, in the absence of cell cycle arrest, apoptosis and senescence. In Aim 2, we will examine whether p53 mediated effects on reactive oxygen species (ROS) production, DNA oxidation damage and glycolysis are critical in suppressing oncogene-mediated tumorigenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Co-regulation of p53 and PD-L1 by the VPRBP-USP2 axis in transcription and ubiquitylation
-
批准号:10439098
-
项目类别:
-
资助金额:$46.84万
-
财政年份:2022
-
负责人:Wei Gu
-
依托单位:
Co-regulation of p53 and PD-L1 by the VPRBP-USP2 axis in transcription and ubiquitylation
-
批准号:10588175
-
项目类别:
-
资助金额:$45.9万
-
财政年份:2022
-
负责人:Wei Gu
-
依托单位:
p53-mediated metabolic regulation in tumor suppression
-
批准号:10474447
-
项目类别:
-
资助金额:$95.26万
-
财政年份:2021
-
负责人:Wei Gu
-
依托单位:
p53-mediated metabolic regulation in tumor suppression
-
批准号:10663249
-
项目类别:
-
资助金额:$95.26万
-
财政年份:2021
-
负责人:Wei Gu
-
依托单位:
Novel small molecule USP7 Inhibitors for p53 activation and cancer therapy
-
批准号:10093308
-
项目类别:
-
资助金额:$37.06万
-
财政年份:2021
-
负责人:Wei Gu
-
依托单位:
p53-mediated metabolic regulation in tumor suppression
-
批准号:10296735
-
项目类别:
-
资助金额:$57.08万
-
财政年份:2021
-
负责人:Wei Gu
-
依托单位:
Novel small molecule USP7 Inhibitors for p53 activation and cancer therapy
-
批准号:10543758
-
项目类别:
-
资助金额:$36.32万
-
财政年份:2021
-
负责人:Wei Gu
-
依托单位:
Novel small molecule USP7 Inhibitors for p53 activation and cancer therapy
-
批准号:10321531
-
项目类别:
-
资助金额:$36.32万
-
财政年份:2021
-
负责人:Wei Gu
-
依托单位:
Noninvasive Risk Stratification of Prostate Cancer Using Cell-Free Nucleic Acids
-
批准号:10301134
-
项目类别:
-
资助金额:$27.37万
-
财政年份:2020
-
负责人:Wei Gu
-
依托单位:
Noninvasive Risk Stratification of Prostate Cancer Using Cell-Free Nucleic Acids
-
批准号:10217044
-
项目类别:
-
资助金额:$28.37万
-
财政年份:2020
-
负责人:Wei Gu
-
依托单位:
Noninvasive Risk Stratification of Prostate Cancer Using Cell-Free Nucleic Acids
-
批准号:10456843
-
项目类别:
-
资助金额:$28.46万
-
财政年份:2020
-
负责人:Wei Gu
-
依托单位:
Noninvasive Risk Stratification of Prostate Cancer Using Cell-Free Nucleic Acids
-
批准号:9981707
-
项目类别:
-
资助金额:$1.09万
-
财政年份:2018
-
负责人:Wei Gu
-
依托单位:
Noninvasive Risk Stratification of Prostate Cancer Using Cell-Free Nucleic Acids
-
批准号:9754043
-
项目类别:
-
资助金额:$28.46万
-
财政年份:2018
-
负责人:Wei Gu
-
依托单位:
p53 acetylation in ferroptosis and tumor suppression
-
批准号:10051413
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2017
-
负责人:Wei Gu
-
依托单位:
Mechanisms of targeting oncoprotein SET in tumor suppression
-
批准号:10117198
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2017
-
负责人:Wei Gu
-
依托单位:
Mechanisms of targeting oncoprotein SET in tumor suppression
-
批准号:9889054
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2017
-
负责人:Wei Gu
-
依托单位:
HAUSP inhibitors in p53-wild type and p53-mutant tumors
-
批准号:8861228
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2015
-
负责人:Wei Gu
-
依托单位:
HAUSP inhibitors in p53-wild type and p53-mutant tumors
-
批准号:9054821
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2015
-
负责人:Wei Gu
-
依托单位:
Regulation of SLC7A11 by p53 in cancer metabolism
-
批准号:9184541
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2015
-
负责人:Wei Gu
-
依托单位:
Regulation of Mdmx stability and subcellular localization by ubiquitination
-
批准号:8271769
-
项目类别:
-
资助金额:$30.2万
-
财政年份:2012
-
负责人:Wei Gu
-
依托单位:
海外基金